Personalis

170 articles with Personalis

• Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics

  8/17/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics.

• Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 16, 2022

  8/16/2022

  Personalis, Inc. announced that, effective on August 15, 2022, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of its common stock and restricted stock units covering an aggregate of 70,000 shares of its common stock to two new employees under Personalis’ 2020 Inducement Plan.

• Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers

  8/15/2022

  Personalis, Inc. has announced a collaboration with BC Cancer to deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal and pancreatic cancers.

• Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

  8/4/2022

  Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022.

• Personalis Reports Second Quarter 2022 Financial Results

  8/3/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022.

• Personalis to Announce Second Quarter 2022 Financial Results

  7/20/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022.

• Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease

  7/12/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.

• GenomOncology Selected by Personalis to Support MRD and SNV Analysis for NeXT Personal™ Assay

  7/12/2022

  GenomOncology announced that the GenomOncology Pathology Workbench has been selected by Personalis to support its NeXT Personal assay for molecular residual disease detection.

• Personalis Reports First Quarter 2022 Financial Results

  5/4/2022

  Personalis, Inc., a leader in advanced genomics for precision oncology, reported financial results for the first quarter ended March 31, 2022.

• Personalis to Present at Upcoming Investor Conferences - Apr 28, 2022

  4/28/2022

  Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will present at the following investor conferences.

• Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales

  4/21/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales.

• Personalis to Announce First Quarter 2022 Financial Results

  4/20/2022

  Personalis, Inc., a leader in advanced genomics for cancer, announced that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022.

• Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene

  4/12/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, "A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity," in Nature Communications.

• Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform

  4/12/2022

  Personalis, Inc. announced the issuance of a key US Patent related to its industry-leading minimal residual disease (MRD) and recurrence platform, NeXT Personal.

• Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022

  4/11/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced its co-authorship of a study with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to be presented during the American Association for Cancer Research Annual Meeting 2022 from April 8-13, 2022.

• Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference

  3/31/2022

  Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 2:15 p.m. Eastern Time.

• Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors

  3/24/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that Karin Eastham has been appointed as Personalis’ new Board Chair effective as of Personalis’ Annual Meeting of Stockholders on May 17, 2022.

• Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022

  3/23/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held in-person and online, April 8-13, 2022.

• Personalis Reports Fourth Quarter and Full Year 2021 Financial Results

  2/24/2022

  Personalis, Inc., a leader in advanced genomics for precision oncology, reported financial results for the fourth quarter and full year ended December 31, 2021.

• Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection

  2/15/2022

  Personalis, Inc. today announced a strategic collaboration with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support clinical diagnostic testing in patients with advanced solid tumors and hematological malignancies.